English, Article edition: Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients W. Ken Redekop; Ewa Orlewska; Pawel Maciejewski; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119505
Physical Description
  • article
Language
  • English

Edition details

Title
  • Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients
Author
  • W. Ken Redekop
  • Ewa Orlewska
  • Pawel Maciejewski
  • Frans F.H. Rutten
  • Louis W. Niessen
Physical Description
  • article
Notes
  • Objectives: To estimate the long-term impact of treatment with perindopril on costs and health effects in patients with stable coronary artery disease in Poland. Methods: The cost-effectiveness analysis was based on data from a randomized double-blind, placebo-controlled trial. A decision-tree analysis was employed, including Monte Carlo and bootstrapping techniques. This study was a sub-study of the EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease) trial (n =​ 12_218; mean follow-up 4.2 years). Resource use was based on data from Polish EUROPA study patients (n =​ 1251), while effectiveness was based on the whole EUROPA study. The health gain of perindopril in life-years was based on overall EUROPA study results, and the adapted Polish life expectancy of patients not dying during the trial. Costs were calculated in new Polish zloty (PLN), year 2003 values; _1_=​_PLN4.053. Only direct healthcare costs related to cardiovascular events and medication use were studied. Results: When observed mortality was combined with life expectancy beyond the end of the study, perindopril use showed a gain in life expectancy of 0.182 life-years (SD_+-_0.129) at a cost of PLN1983 (SD +- 103) with discounting of 5% per annum on costs and no discounting on effects. This resulted in an incremental cost-effectiveness ratio (ICER) of PLN10_896 per life-year gained. The probability that the ICER for perindopril was below the threshold of PLN60_000 was 88%. The overall results were insensitive to discount rates for costs and life-years. Conclusions: Perindopril leads to a reduction in the risk of coronary events among patients with stable heart disease. When the expected improvement in life expectancy is combined with associated medical costs, there is a high probability that perindopril is cost effective, given the threshold of PLN60_000 per life-year gained. DOI: 10.2165/​0019053-200826100-00006
  • Coronary-artery-disease, Cost-effectiveness, Perindopril
  • RePEc:wkh:phecon:v:26:y:2008:i:10:p:861-877
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment